ORPHA:66661
Mast cell sarcoma
Publications
2,417
Trials
0
Interventional, condition-specific
Researchers
1,204
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Mast cell sarcoma is a rare, neoplastic disease characterized by locally destructive sarcoma-like growth of a solitary mass, composed of atypical mast cells, and without systemic involvement. It can affect any organ and the symptoms depend on the location. Cells are medium to large, pleomorphic or epithelioid, with oval, bilobed or multilobulated nuclei, sometimes prominent multinucleated giant cells. The disease closely resembles other neoplasms and may share associated markers, however the tumor is positive for mast cell tryptase.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019024
- MeSH:D012515
- UMLS:C0036221
- NCIT:C9348
Additional Mondo synonyms (4)
MCS · mast cell sarcoma · mast-cell sarcoma · sarcoma of mast cell
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,417 matched papers (257 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 1655 for broader category sarcoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,417
2,417 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,417 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
257 in the last 10 years · low confidence
Phrase hits: 2,417 · MeSH hits: 43
Who's working on it?
1,204
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Hermine O9 papers · 2025
Imagine Institute Université de Paris, Sorbonne, Institut national de la santé et de la recherche médicale U1163, Centre national de référence des mastocytoses, Hôpital Necker, Assistance publique hôpitaux de Paris, France.
Papers in Europe PMC - 02Valent P9 papers · 2026
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
Papers in Europe PMC - 03Arock M8 papers · 2026
Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.
Papers in Europe PMC - 04Akin C7 papers · 2026
Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Papers in Europe PMC - 05Horny HP7 papers · 2025
Institute of Pathology, Paracelsus Medical University Salzburg, Austria.
Papers in Europe PMC - 06Sperr WR6 papers · 2026
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
Papers in Europe PMC - 07Orfao A5 papers · 2026
Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL) Instituto Biosanitario de Salamanca (IBSAL) and Department of Medicine, University of Salamanca, Spain.
Papers in Europe PMC - 08Reiter A5 papers · 2024
Department of Hematology and Oncology, University Hospital Mannheim, Germany.
Papers in Europe PMC - 09George TI4 papers · 2025
Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
Papers in Europe PMC - 10Hartmann K4 papers · 2026
Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Switzerland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 1,655 trials are registered for sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
1,655 interventional trials matched sarcoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: sarcoma
1,655
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07359053·RECRUITING·MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Conditions: Sarcoma·Matched via name phrase
- NCT06805773·RECRUITING·Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Conditions: Sarcoma·Matched via name phrase
- NCT07460986·NOT YET RECRUITING·A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA
Conditions: Sarcoma of Soft Tissue·Matched via name phrase
- NCT07134192·RECRUITING·Fluorescence-Guided Optimization of Sarcoma Margins
Conditions: Soft Tissue Sarcoma of the Trunk and Extremities · Sarcoma·Matched via name phrase
- NCT01659203·RECRUITING·Proton or Photon RT for Retroperitoneal Sarcomas
Conditions: Retroperitoneal Sarcoma·Matched via name phrase
- NCT07032285·RECRUITING·Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Conditions: Soft Tissue Sarcoma (STS)·Matched via name phrase
- NCT07308886·RECRUITING·Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Conditions: Kaposi Sarcoma·Matched via name phrase
- NCT06789666·RECRUITING·Digital Art Therapy for Young Cancer Survivors
Conditions: Cancer · Pediatric Cancer · Pediatric Malignancies · Pediatric Sarcoma of Soft Tissue·Matched via name phrase
- NCT07052383·RECRUITING·Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Conditions: Osteosarcoma · Soft Tissue Sarcoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT05918640·RECRUITING·Lurbinectedin in FET-Fused Tumors
Conditions: Ewing Sarcoma · Desmoplastic Small Round Cell Tumor · Pediatric Cancer · Undifferentiated Sarcoma·Matched via name phrase
- NCT06371768·RECRUITING·Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Conditions: Cancer · Breast Cancer · Colorectal Cancer · Sarcoma·Matched via name phrase
- NCT04698785·RECRUITING·Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Conditions: Bone Sarcoma · Osteosarcoma·Matched via name phrase
- NCT05182164·RECRUITING·Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Conditions: Soft Tissue Sarcoma Adult · Advanced Soft-tissue Sarcoma · Ewing Sarcoma · Osteosarcoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mast cell sarcoma" OR "mast-cell sarcoma" OR "sarcoma of mast cell" OR "sarcoma of the mast cell"
MeSH descriptor terms unioned into the query: Mast-Cell Sarcoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mast cell sarcoma" OR "mast-cell sarcoma" OR "sarcoma of mast cell" OR "sarcoma of the mast cell"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"sarcoma"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MCS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (2417) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T01:23:14.393Z
